Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6064094 | Journal of Allergy and Clinical Immunology | 2015 | 16 Pages |
Abstract
This multicenter study demonstrated that HSCT in patients with CVID was beneficial in most surviving patients; however, there was a high mortality associated with the procedure. Therefore this therapeutic approach should only be considered in carefully selected patients in whom there has been extensive characterization of the immunologic and/or genetic defect underlying the CVID diagnosis. Criteria for patient selection, refinement of the transplantation protocol, and timing are needed for an improved outcome.
Keywords
GvHDHCT-CIPIDcGVHDRICaGVHDCVIDHSCTESIDEuropean Society for ImmunodeficienciesSurvivalAcute graft-versus-host diseaseGraft-versus-host diseaseChronic graft-versus-host diseaseReduced-intensity conditioningMyeloablative conditioningcytomegalovirusCMVMortalitybone marrowMACOutcomeHypogammaglobulinemiaHematopoietic stem cell transplantationprimary immunodeficiencyCommon variable immunodeficiency
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Claudia MD, Andrew R. MD, Caroline MD, PhD, Ansgar MD, Manfred MD, Reinhard MD, Mike MD, Bernd MD, Andreas MD, Ingmar PhD, Deborah BSc, Goetz MD, Hermann MD, Ulrich MD, Thorsten MD, Karl-Walter MD, Sigune MD, Lorena MD, Marta MD, PhD,